BridgeMD
New treatment option for Osteochondral Defect
Official title Descriptive Study of the Reconstruction of Osteochondral Lesions of the Knee: Clinical and Imaging Results
ClinicalTrials.gov ID: NCT03908931
What this study is testing
- What it's testing
- The purpose of this study is to evaluate the clinical results and MRI imaging of autologous cartilage reconstructions or collagen matrix of the knee. There is currently little data in the literature on clinical outcomes and imaging of this type of lesion.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- cartilaginous reconstruction by autologous transplant or collagenous chondro-inducing knee matrix
- \> 18 years
You likely can't join if
- Other cartilaginous reconstruction techniques,
- other than knee joint
The study team makes the final eligibility decision.
Where it's taking place
- Le Chesnay, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Le Chesnay, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.